查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血脂异常药物市场，按药物类别、按应用、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1388770

血脂异常药物市场，按药物类别、按应用、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Dyslipidemia Drugs Market, By Drug Class, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年血脂异常药物市场规模为156.5343亿美元，2023年至2030年复合CAGR为5.5%。

血脂异常是患者普遍存在的疾病，对心血管疾病的发生和进展构成重大风险。这些疾病的特征是总胆固醇 (TC)、三酸甘油酯 (TG) 和低密度脂蛋白胆固醇 (LDL-C) 水平升高。血脂异常药物用于治疗这种疾病，这种疾病的定义是血液中脂质（脂肪）水平异常。降低胆固醇水平的治疗基石包括传统的降血脂疗法 (LLT)，例如他汀类药物、依折麦布和 PCSK9 抑制剂，并结合维持健康的生活方式。他汀类药物透过选择性抑制 HMG-CoA 还原酶来降低细胞胆固醇含量。

血脂异常药物市场-市场动态

久坐的生活方式、不健康的饮食习惯和肥胖的盛行率不断增加

由于久坐的生活方式、不健康的饮食习惯、肥胖等因素，血脂异常的发生率增加。随着社会经济发展导致生活方式进一步改变，这种趋势预计将持续下去。根据国家生物技术资讯中心的数据，目前血脂异常的盛行率为66.7%，其中高LDL-C、高三酸甘油酯、高总胆固醇和低HDL-C的盛行率分别为49.5%、40.2% 、30.8%和分别为 16.5%。血脂异常药物市场预计将成长，以满足对有效治疗不断增长的需求。此外，药物配方和作用机制的创新为新型和增强药物带来了前景。然而，替代疗法的可用性可能会阻碍市场成长。

血脂异常药物市场 - 关键见解

  • 根据我们的研究分析师分享的分析，全球血脂异常药物市场预计在预测期内（2023-2030）每年将以 5.5% 左右的CAGR成长
  • 由于久坐的生活方式、不健康的饮食习惯和肥胖的流行，预计对血脂异常治疗的需求将显着增长
  • 根据药物类别细分，预计他汀类药物将在 2022 年占据最大市场份额
  • 从应用细分来看，医院药局是2022年的主导类型
  • 按地区划分，北美是 2022 年的主要收入来源

血脂异常药物市场-細項分析：

全球血脂异常药物市场根据药物类别、应用和地区进行细分。

市场依药物类别分为两类：非他汀类药物和他汀类药物。他汀类药物在市场上占据主导地位。他汀类药物是治疗血脂异常的常用药物，特别是在控制胆固醇水平升高方面。它们在降低 LDL（低密度脂蛋白）胆固醇（俗称坏胆固醇）方面非常有效，因此是治疗这种疾病最常用的药物之一。

根据应用市场分为三类：医院药局、零售药局和其他。医院药房占据市场主导地位。血脂异常药物的管理和应用在医院环境中至关重要，因为患有心血管疾病（包括血脂异常）的患者通常从医院药房接受初始或持续治疗。

血脂异常药物市场-地理洞察

该市场广泛覆盖北美、欧洲、亚太地区、拉丁美洲、中东和非洲。这些区域根据进行商业活动的国家进一步细分。由于生物技术的进步和医疗设施的升级，北美可能会引领血脂异常药物市场的扩张。北美的医疗基础设施高度发达，技术先进，有助于有效诊断、治疗和控制血脂异常等一系列疾病。 《全球视野下的美国医疗保健》显示，2021年，美国医疗支出占GDP的17.8%，几乎是经合组织国家中位数的两倍。此外，该地区生物技术和製药公司也大量集中，目前正在进行广泛的研究和开发活动。由于对血脂异常药物研发的投资不断增加，欧洲是第二大血脂异常药物市场。

血脂异常药物市场-竞争格局：

药品行销服务 (PMS) 对于製药公司至关重要，因为它们在公司和医生之间建立了联繫。他们还充当本地和全球医生和患者之间的桥樑。血脂异常药物的竞争格局包括着名的製药公司、其主要产品、市场份额以及解决这种疾病的策略。在这个竞争激烈的市场中，策略包括持续的研究和开发努力，以创造更有效和更安全的药物，积极的营销活动以影响医生和患者，以及战略合作以加强市场主导地位。

最近的发展：

2023 年7 月，诺华表示，美国FDA 已授权对Leqvio (inclisiran) 的标籤进行修改，以便更早地将其作为饮食和他汀类药物治疗的补充，用于心臟病风险较高的高LDL-C患者。

目录

第 1 章：血脂异常药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的血脂异常药物市场片段
    • 血脂异常药物市场片段（依应用）
    • 按国家/地区分類的血脂异常药物市场片段
    • 按地区分類的血脂异常药物市场片段
  • 竞争洞察

第 3 章：血脂异常药物主要市场趋势

  • 血脂异常药物市场驱动因素
    • 市场驱动因素的影响分析
  • 血脂异常药物市场限制
    • 市场限制影响分析
  • 血脂异常药物市场机会
  • 血脂异常药物市场未来趋势

第 4 章：血脂异常药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：血脂异常药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：血脂异常药物市场格局

  • 2022 年血脂异常药物市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：血脂异常药物市场 - 依药物类别

  • 概述
    • 按药物类别分類的细分市场份额分析
    • 非他汀类药物
      • 胆汁酸螯合剂
      • 胆固醇吸收抑制剂
      • 贝特类
      • 烟碱酸
      • 其他的
    • 他汀类药物
      • 高强度
      • 中等强度
      • 低强度

第 8 章：血脂异常药物市场 -按应用

  • 概述
    • 按应用的细分市场占有率分析
    • 医院药房
    • 零售药房
    • 其他的

第 9 章：血脂异常药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美血脂异常药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按应用）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲血脂异常药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模和预测（按应用）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区血脂异常药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（按应用）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲血脂异常药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按应用）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲血脂异常药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按应用）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析 - 血脂异常药物产业

  • 竞争仪表板
  • 公司简介
    • Novartis AG
    • Mylan NV
    • Bristol-Myers Squibb Company
    • AstraZeneca plc
    • Shionogi & Co., Ltd.
    • Pfizer, Inc.
    • Abbott Laboratories.
    • Merck & Co., Inc.
    • Bayer AG
    • Amgen, Inc.

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1824

REPORT HIGHLIGHT

Dyslipidemia Drugs Market size was valued at USD 15,653.43 Million in 2022, expanding at a CAGR of 5.5% from 2023 to 2030.

Dyslipidemias, prevalent disorders among patients, pose significant risks for the development and progression of cardiovascular diseases. These disorders are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). Medications known as dyslipidemia drugs are utilized to treat this medical condition, which is defined by abnormal lipid (fat) levels in the bloodstream. The cornerstone of treatment to lower cholesterol levels involves conventional lipid-lowering therapies (LLTs), such as statins, ezetimibe, and PCSK9 inhibitors, in conjunction with maintaining a healthy lifestyle. Statins work by reducing cellular cholesterol content through the selective inhibition of the enzyme HMG-CoA reductase.

Dyslipidemia Drugs Market- Market Dynamics

Increasing Prevalence of sedentary lifestyles, unhealthy dietary habits, and obesity

The incidence of dyslipidemia has increased due to factors such as sedentary lifestyles, unhealthy dietary habits, and obesity. This trend is expected to continue as socio-economic development leads to further lifestyle changes. According to the National Center for Biotechnological Information, the prevalence of dyslipidemia is currently at 66.7%, with high LDL-C, elevated triglyceride, elevated total cholesterol, and low HDL-C being prevalent in 49.5%, 40.2%, 30.8%, and 16.5% of cases, respectively. The dyslipidemia drugs market is expected to grow to meet the rising demand for effective treatments. Furthermore, Innovations in drug formulations and mechanisms of action present prospects for novel and enhanced medications. However, the availability of alternative therapies may hamper the market growth.

Dyslipidemia Drugs Market- Key Insights

  • As per the analysis shared by our research analyst, the global Dyslipidemia Drugs market is estimated to grow annually at a CAGR of around 5.5% over the forecast period (2023-2030)
  • The demand for dyslipidemia treatments is expected to grow significantly due to Increasing Prevalence of sedentary lifestyles, unhealthy dietary habits, and obesity
  • Based on Drug Class segmentation, statins drugs were predicted to show maximum market share in the year 2022
  • Based on Application segmentation, Hospital pharmacy was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Dyslipidemia Drugs Market- Segmentation Analysis:

The Global Dyslipidemia Drugs Market is segmented on the basis of Drug Class, Application, and Region.

The market is divided into two categories based on Drug Class: Non-statins drugs and statins drugs. statins drugs dominate the market. Statins are frequently prescribed drugs for the treatment of dyslipidemia, particularly in the management of elevated levels of cholesterol. They are highly effective in reducing LDL (low-density lipoprotein) cholesterol, commonly known as bad cholesterol, and are therefore one of the most commonly prescribed medications for this condition.

The market is divided into three categories based on Application: Hospital pharmacy, Retail pharmacy, and Others. Hospital pharmacy dominates the market. The management and Application of dyslipidemia drugs are of utmost importance in hospital settings, as patients with cardiovascular conditions, including dyslipidemia, often receive their initial or ongoing treatment from hospital pharmacies.

Dyslipidemia Drugs Market- Geographical Insights

This market is extensive over North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. These areas are further subdivided based on the countries bringing commerce. Because of biotechnological advancements and upgrades in healthcare facilities North America is likely to lead in the expansion of the Dyslipidemia Drugs market. The healthcare infrastructure in North America is highly developed and technologically advanced, facilitating the effective diagnosis, treatment, and control of a range of medical conditions, such as dyslipidemia. The U.S. Health Care from a Global Perspective showed that in 2021, the U.S. disbursed 17.8 % of GDP on medical care, nearly double as much as the median OECD nations. Also, there is a significant concentration of biotechnology and pharmaceutical firms in the area, which are currently involved in extensive research and development activities. Europe is the second largest Dyslipidemia Drugs market, due to growing investment in Research and development of Dyslipidemia Drugs.

Dyslipidemia Drugs Market- Competitive Landscape:

Pharmaceutical marketing services (PMS) are essential for pharmaceutical companies as they establish connections between the company and physicians. They also serve as a bridge between physicians and patients, both locally and globally. The competitive landscape of dyslipidemia drugs includes prominent pharmaceutical companies, their primary products, market share, and strategies to address this medical condition. In this competitive market, strategies involve continuous research and development efforts to create more effective and safer medications, assertive marketing campaigns to influence physicians and patients, and strategic collaborations to strengthen market dominance.

Recent Developments:

on July 2023, Novartis said that the US FDA had authorized a label modification for Leqvio (inclisiran) to allow for earlier usage as an addition to diet and statin treatment in patients with high LDL-C who are at greater risk of heart disease.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DYSLIPIDEMIA DRUGS MARKET KEY PLAYERS

  • Novartis AG
  • Mylan N.V.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Shionogi & Co., Ltd.
  • Pfizer, Inc.
  • Abbott Laboratories.
  • Merck & Co., Inc.
  • Bayer AG
  • Amgen, Inc.

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY DRUG CLASS

  • Non-statins drugs
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitor
  • Fibrates
  • Nicotinic Acid
  • Others
  • Statin drugs
  • High intensity
  • Moderate intensity
  • Low intensity

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY APPLICATION

  • Hospital pharmacy
  • Retail pharmacy
  • Others

GLOBAL DYSLIPIDEMIA DRUGS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Dyslipidemia Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Dyslipidemia Drugs Market Snippet by Drug Class
    • 2.1.2. Dyslipidemia Drugs Market Snippet by Application
    • 2.1.3. Dyslipidemia Drugs Market Snippet by Country
    • 2.1.4. Dyslipidemia Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Dyslipidemia Drugs Key Market Trends

  • 3.1. Dyslipidemia Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Dyslipidemia Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Dyslipidemia Drugs Market Opportunities
  • 3.4. Dyslipidemia Drugs Market Future Trends

4. Dyslipidemia Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Dyslipidemia Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Dyslipidemia Drugs Market Landscape

  • 6.1. Dyslipidemia Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Dyslipidemia Drugs Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Non-statins drugs
      • 7.1.2.1. Bile Acid Sequestrants
      • 7.1.2.2. Cholesterol Absorption Inhibitor
      • 7.1.2.3. Fibrates
      • 7.1.2.4. Nicotinic Acid
      • 7.1.2.5. Others
    • 7.1.3. Statin drugs
      • 7.1.3.1. High intensity
      • 7.1.3.2. Moderate intensity
      • 7.1.3.3. Low intensity

8. Dyslipidemia Drugs Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 8.1.2. Hospital pharmacy
    • 8.1.3. Retail pharmacy
    • 8.1.4. Others

9. Dyslipidaemia Drugs Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Dyslipidemia Drugs Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Dyslipidemia Drugs Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Dyslipidemia Drugs Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Dyslipidemia Drugs Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Dyslipidemia Drugs Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Dyslipidemia Drugs Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Novartis AG
    • 10.2.2. Mylan N.V.
    • 10.2.3. Bristol-Myers Squibb Company
    • 10.2.4. AstraZeneca plc
    • 10.2.5. Shionogi & Co., Ltd.
    • 10.2.6. Pfizer, Inc.
    • 10.2.7. Abbott Laboratories.
    • 10.2.8. Merck & Co., Inc.
    • 10.2.9. Bayer AG
    • 10.2.10. Amgen, Inc.

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Dyslipidemia Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Dyslipidemia Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Dyslipidemia Drugs Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Dyslipidemia Drugs Market, by Application 2018-2030 (USD Million)
  • TABLE Dyslipidemia Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Dyslipidemia Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Dyslipidemia Drugs Market, by Application, 2018-2030 (USD Million)